NINLARO® (ixazomib) | Healthcare Professional Information

IN THE MARATHON OF MYELOMA TREATMENT,

ARE YOU DROPPING THE PROTEASOME INHIBITOR TOO SOON?

Continuous treatment with a proteasome inhibitor (PI)–based regimen is associated with clinical benefits, including for patients with high-risk cytogenetics.^1-3 However, many patients who have had 1 prior therapy receive injectable PIs for only 4 to 7 months.^4,5

The NINLARO^® (ixazomib) regimen extended median PFS by ~6 months (median: 20.6 vs 14.7 months) vs placebo regimen in patients with multiple myeloma who have received at least 1 prior therapy.^1*†

NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

SEE THE PATH TO EXTENDED PFS
VIEW SAFETY

^*The NINLARO regimen included NINLARO+lenalidomide+dexamethasone. The placebo regimen included placebo+lenalidomide+dexamethasone.
^†95% CI, 17.0-NE and 95% CI, 12.9-17.6, respectively; HR=0.74 (95% CI, 0.59-0.94); P=0.012.
NE=not evaluable; PFS=progression-free survival.

^*The NINLARO regimen included NINLARO+lenalidomide+dexamethasone. The placebo regimen included placebo+lenalidomide+dexamethasone.
^†95% CI, 17.0-NE and 95% CI, 12.9-17.6, respectively; HR=0.74 (95% CI, 0.59-0.94); P=0.012.
NE=not evaluable; PFS=progression-free survival.

Expert Insights

See what Dr. Vescio has to say about multiple myeloma and the NINLARO treatment regimen.

Watch now

Dr. Vescio is a paid consultant of Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Takeda Oncology Patient Support Program

Your connection for coverage support, financial assistance, and educational resources.

Enrollment Form

Dr. Vescio is a paid consultant of Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.